Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Marysa Leya

Interventional Cardiology Chicago, IL Medical Doctor

NPI 1790176618 CMS profile 1325443

676 N Saint Clair St Ste 600, Chicago, IL 60611

Open in the dashboard

General payments

$32,973

173 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Marysa Leya of Chicago, IL is reported in the CMS Open Payments database as having received $32,973 across 173 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 82nd percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,701 25
2024 General $3,480 42
2023 General $10,971 58
2022 General $15,800 32
2021 General $837 11
2020 General $20 1
2019 General $164 4

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Marysa Leya
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Marysa Leya were reported at $1,701. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Marysa Leya Interventional Cardiology median Middle half National median
2019 $164 $1,097 $329–$3,048 $163
2020 $20 $473 $161–$1,480 $114
2021 $837 $677 $233–$1,827 $132
2022 $15,800 $978 $333–$2,724 $149
2023 $10,971 $1,136 $382–$2,986 $160
2024 $3,480 $1,181 $395–$3,326 $164
2025 $1,701 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $17,384 38 payments
  2. Abbott Laboratories $7,175 21 payments
  3. Edwards Lifesciences Corporation $3,113 36 payments
  4. Boston Scientific Corporation $1,500 25 payments
  5. Medical Device Business Services, Inc. $695 5 payments
  6. Penumbra, Inc. $581 5 payments
  7. Cardiovascular Systems Inc. $385 5 payments
  8. Biosense Webster, Inc. $377 4 payments
  9. Abiomed $296 4 payments
  10. Cardiva Medical, Inc. $255 5 payments
  11. Other $1,213 25 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Grant $19,000 3 payments
  2. Food and Beverage $9,618 143 payments
  3. Travel and Lodging $4,071 24 payments
  4. Education $284 3 payments
Products named General payments · program years 2019–2025
  1. COREVALVE EVOLUT R $9,206 35 payments
  2. RESOLUTE ONYX $8,052 2 payments
  3. EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) $1,853 17 payments
  4. MITRACLIP $1,099 9 payments
  5. Carto 3 $695 5 payments
  6. Stingray $620 5 payments
  7. Indigo System $581 5 payments
  8. PASCAL $381 3 payments
  9. NUVISION ICE CATHETER $377 4 payments
  10. SAPIEN 3 Ultra RESILIA $356 8 payments
  11. Other $4,533 76 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

87

Median for Hospitalist: 109

Drug cost

$992

Median for Hospitalist: $6,399

Branded share of claims

85.1%

Median for Hospitalist: 19.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Clopidogrel Clopidogrel Bisulfate Brand 74 $798
Atorvastatin Calcium Generic 13 $194

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,498 Part D prescribers listed as Hospitalist; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 44 billing codes

Paid by Medicare

$65,325

Medicare's payments for the services billed

Medicare patients

214

Average age 74

Services billed

548

89 women, 125 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 75%
Heart failure 53%
Chronic kidney disease 44%
Arthritis 41%
Atrial fibrillation 39%
Diabetes 38%
COPD 26%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XARELTO
  • Janssen Pharmaceuticals, Inc $21
$21 — —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $17
$17 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

173 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record